Physician profile
Daniel B Rootman
NPI 1871849091
$246,882.43
in general payments reported to CMS, 2019-2025
13 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $20K · 2021: $41K · 2022: $20K · 2023: $57K · 2024: $35K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $39K · Travel and Lodging: $17K · Food and Beverage: $4,196 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $46,737.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,012.50 |
| Consulting Fee | $39,427.75 |
| Travel and Lodging | $17,312.90 |
| Food and Beverage | $4,196.10 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $144,009.26 | 2019-2023 | Tepezza |
| Amgen INC. | $58,139.48 | 2024-2025 | Tepezza |
| Argenx US, INC. | $41,174.46 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Celularity INC. | $2,018.75 | 2020 | |
| Axogen | $250.14 | 2023-2025 | Avance Nerve Graft |
| Biotissue Holdings INC. | $246.62 | 2025 | |
| Merz North America, INC. | $227.10 | 2019-2020 | |
| Aerin Medical INC. | $188.14 | 2025 | |
| Medtronic, INC. | $153.46 | 2025 | Stealthstation S8 Platform |
| Abbvie INC. | $146.77 | 2024 | |
| Genentech USA, INC. | $143.65 | 2022 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Merz Pharmaceuticals, LLC | $84.61 | 2023-2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rootman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.